Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 2/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 3/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18205210 | 0.90 | MEN1 (0.58) | CARM1HDAC4MEN1KMT2AMAPT | |
| SCHEMBL28928597 | 0.80 | PRMT5 (0.51) | CARM1HDAC4POLBNAMPTPRMT5 | |
| SCHEMBL29758947 | 0.80 | PRMT5 (0.51) | CARM1HDAC4POLBNAMPTPRMT5 | |
| SCHEMBL18212444 | 0.80 | PRMT5 (0.51) | CARM1HDAC4POLBNAMPTPRMT5 | |
| SCHEMBL4896798 | 0.79 | CARM1 (0.45) | CARM1MEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL18210490 | 0.78 | CARM1 (0.44) | CARM1MEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL18205240 | 0.78 | HDAC4 (0.52) | HDAC4MEN1KMT2A | |
| SCHEMBL18205172 | 0.76 | HDAC4 (0.52) | CARM1HDAC4MEN1KMT2AMAPT | |
| SCHEMBL18205171 | 0.73 | DPP8 (0.53) | NAMPTNOTUM | |
| SCHEMBL29563547 | 0.73 | CARM1 (0.61) | CARM1MEN1KMT2APRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190202795-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2019-07-04 | — | — | US | disclosed |
| US-10053434-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2018-08-21 | — | — | US | disclosed |
| EP-3291810-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation, Inc. (US) | 2018-03-14 | — | — | EP | disclosed |
| WO-2016179554-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2016-11-10 | — | — | WO | disclosed |
| US-20160326124-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202795-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | CARM1 59/4885HDAC4 10/4885MEN1 3789/4885 |
| US-10053434-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | HDAC1, HDAC7, HDAC5 | CARM1 59/4885HDAC4 10/4885MEN1 3789/4885 |
| US-20160326124-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | CARM1 59/4885HDAC4 10/4885MEN1 3789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.